legionnair
diseas
rel
rare
caus
communityacquir
pneumonia
caus
legionella
speci
howev
patient
hospit
legionnair
diseas
requir
invas
mechan
ventil
averag
mortal
rate
sporad
diseas
rang
legionnair
diseas
caus
inhal
legionella
speci
intracellular
gramneg
bacilli
ubiquit
found
environ
host
risk
factor
legionnair
diseas
includ
male
gender
age
older
year
cigarett
smoke
diabet
endstag
renal
failur
organ
transplant
immunosuppress
glucocorticoid
antireject
drug
follow
organ
transplant
travel
import
underappreci
risk
factor
associ
legionellosi
commun
set
treatment
option
legionnair
diseas
includ
macrolid
fluoroquinolon
tetracyclin
howev
prefer
therapi
immunocompromis
patient
legionnair
diseas
includ
levofloxacin
azithromycin
describ
immunocompromis
sever
ill
patient
legionnair
diseas
also
allergi
fluoroquinolon
macrolid
success
treat
use
tigecyclin
third
gener
glycylcyclin
indic
tigecyclin
may
serv
safe
effect
altern
therapeut
option
treatment
legionnair
diseas
select
case
caucasian
man
present
emerg
depart
autumn
one
week
dyspnea
product
cough
myalgia
fever
deni
chest
pain
hemoptysi
past
medic
histori
signific
hypertens
diabet
mellitu
chronic
kidney
diseas
nonhodgkin
lymphoma
receipt
allogen
stem
cell
transplant
year
prior
given
prior
complic
due
graft
versu
host
diseas
receiv
prednison
mainten
dose
mg
daili
sever
year
multipl
document
allergi
penicillin
sulfa
drug
macrolid
fluoroquinolon
report
reaction
includ
rash
hive
anaphylaxi
approxim
one
week
prior
onset
symptom
travel
midwest
unit
state
partner
stay
variou
hotel
upon
arriv
hospit
note
heart
rate
beat
per
minut
blood
pressur
mmhg
respiratori
rate
breath
per
minut
oxygen
satur
requir
eight
liter
supplementari
oxygen
oral
temperatur
acut
respiratori
distress
evid
decreas
breath
sound
crackl
bilater
note
normal
heart
sound
without
murmur
rub
gallop
rash
examin
two
set
blood
cultur
collect
sputum
sampl
sent
cultur
well
stain
polymeras
chain
reaction
pcr
test
pneumocysti
jirovecii
p
jirovecii
nasopharyng
sampl
collect
respiratori
viru
pcr
test
influenza
b
respiratori
syncyti
viru
b
coronaviru
parainfluenza
viru
rhinoviru
enteroviru
adenoviru
bocaviru
metapneumoviru
addit
serum
cytomegaloviru
cmv
pcr
legionella
urin
antigen
sent
empir
start
meropenem
vancomycin
oseltamivir
intraven
pentamidin
despit
initi
broad
spectrum
antimicrobi
continu
deterior
increas
oxygen
demand
persist
fever
hemodynam
instabl
worsen
radiograph
infiltr
figur
show
worsen
bilater
pulmonari
opacif
arrow
sputum
blood
cultur
neg
bacteri
growth
sputum
stain
pcr
neg
p
jirovecii
serum
cmv
pcr
neg
nasopharyng
swab
respiratori
viru
test
neg
influenza
b
respiratori
syncyti
viru
b
coronaviru
parainfluenza
viru
rhinoviru
enteroviru
adenoviru
bocaviru
metapneumoviru
howev
legionella
urin
antigen
posit
accord
pharmaci
record
previous
receiv
toler
fiveday
cours
moxifloxacin
approxim
one
year
prior
hospit
admiss
given
diagnosi
legionnair
diseas
intraven
moxifloxacin
therapi
initi
howev
shortli
follow
receipt
first
dose
moxifloxacin
develop
allerg
reaction
gener
erythemat
maculopapular
rash
angioedema
necessit
administr
epinephrin
given
document
allergi
fluoroquinolon
macrolid
hemodynam
instabl
concern
poor
gastrointestin
absorpt
oral
antimicrobi
subsequ
treat
intraven
tigecyclin
initi
load
dose
mg
follow
mg
twice
daili
total
day
therapi
intraven
doxycyclin
readili
avail
institut
oxygen
requir
decreas
fever
resolv
follow
hour
treatment
tigecyclin
antimicrobi
discontinu
diagnosi
legionnair
diseas
made
recurr
infect
three
month
followup
repeat
chest
radiograph
show
resolut
bilater
air
space
opac
later
discuss
north
dakota
depart
health
center
diseas
control
prevent
determin
ongo
outbreak
legionnair
diseas
associ
five
case
period
case
includ
patient
stay
hotel
subsequ
environment
test
hotel
neg
may
impact
recent
deep
clean
hotel
ventil
system
legionnair
diseas
caus
pathogen
first
recogn
follow
commonsourc
outbreak
sever
pneumonia
involv
peopl
american
legion
convent
philadelphia
pennsylvania
outbreak
cluster
case
legionnair
diseas
associ
contamin
cool
tower
whirlpool
hospit
decor
water
fountain
hot
spring
spa
water
birth
legionnair
diseas
associ
prodrom
ill
symptom
includ
fever
headach
myalgia
anorexia
howev
clinic
present
legionnair
diseas
often
nonspecif
difficult
distinguish
caus
communityacquir
pneumonia
blood
sputum
cultur
rel
insensit
diagnos
legionnair
diseas
contrast
urin
antigen
test
sensit
specif
greater
urin
antigen
test
legionella
detect
legionella
pneumophila
serogroup
sensit
detect
pontiac
subtyp
caus
major
case
communityacquir
legionnair
diseas
legionella
urin
antigen
test
often
posit
first
day
ill
remain
posit
sever
week
molecular
test
lower
respiratori
tract
specimen
also
use
identifi
legionella
pneumophila
legionella
speci
pcr
prefer
therapi
immunocompromis
patient
legionnair
diseas
includ
levofloxacin
azithromycin
tigecyclin
third
gener
intraven
glycylcyclin
minocyclin
deriv
inhibit
bacteri
protein
synthesi
bind
bacteri
ribosom
subunit
prior
vitro
anim
model
studi
shown
tigecyclin
achiev
high
intracellular
concentr
howev
demonstr
clinic
effect
tigecyclin
treatment
communityacquir
pneumonia
human
legionnair
diseas
remain
limit
two
prior
case
report
describ
success
use
tigecyclin
treatment
immunocompromis
patient
legionellosi
howev
fluoroquinolon
use
initi
therapi
case
tigecyclin
later
ad
antimicrobi
regimen
recent
publish
case
seri
describ
eight
patient
legionnair
diseas
switch
tigecyclin
often
due
worsen
sepsi
andor
respiratori
statu
follow
initi
exposur
macrolid
andor
fluoroquinolon
therapi
median
three
day
one
eight
patient
receiv
combin
therapi
tigecyclin
plu
either
levofloxacin
azithromycin
part
treatment
regimen
tigecyclin
ad
furthermor
one
patient
case
seri
receiv
day
tigecyclin
monotherapi
receiv
eight
day
azithromycin
prior
switch
therapi
thu
difficult
ascertain
whether
clinic
improv
case
due
addit
tigecyclin
postantibiot
effect
delay
respons
fluoroquinolonemacrolid
therapi
integr
result
two
random
control
trial
show
compar
cure
rate
tigecyclin
levofloxacin
treatment
hospit
patient
communityacquir
pneumonia
small
proport
diagnos
legionnair
diseas
treatment
arm
integr
result
two
random
control
trial
support
earli
use
tigecyclin
empir
treatment
communityacquir
pneumonia
one
trial
permit
switch
oral
levofloxacin
follow
least
three
day
intraven
therapi
evid
clinic
improv
current
evid
albeit
limit
suggest
tigecyclin
may
ad
combin
therapi
sever
case
legionnair
diseas
case
howev
demonstr
tigecyclin
effect
secondlin
treatment
option
legionnair
diseas
set
allergi
tradit
mainstay
therapi
food
drug
administr
fda
approv
new
box
warn
higher
risk
death
among
patient
receiv
tigecyclin
compar
antibiot
particularli
appar
hospitalacquir
pneumonia
ventilatorassoci
pneumonia
fda
health
canada
approv
tigecyclin
treatment
communityacquir
bacteri
pneumonia
complic
skin
soft
tissu
infect
complic
intraabdomin
infect
use
reserv
situat
altern
treatment
suitabl
legionnair
diseas
rare
caus
communityacquir
pneumonia
associ
signific
morbid
mortal
especi
amongst
immunocompromis
individu
although
evid
regard
use
tigecyclin
treat
legionnair
diseas
limit
case
report
provid
evid
support
use
tigecyclin
secondlin
therapeut
option
select
case
fluoroquinolon
macrolid
therapi
may
contraind
human
subject
consent
obtain
particip
studi
complianc
icmj
uniform
disclosur
form
author
declar
follow
paymentservic
info
author
declar
financi
support
receiv
organ
submit
work
financi
relationship
author
declar
financi
relationship
present
within
previou
three
year
organ
might
interest
submit
work
relationship
author
declar
relationship
activ
could
appear
influenc
submit
work
